| Literature DB >> 31269948 |
Mohammad K Parvez1, Mohammed S Al-Dosari2, Ahmed H Arbab2,3, Perwez Alam2, Mansour S Alsaid4, Azmat A Khan5.
Abstract
BACKGROUND: Of over 35 Saudi plants traditionally used to treat liver disorders, majority still lack scientific validations. We therefore, evaluated the anti-oxidative, anti-apoptotic and hepatoprotective potential of Solanum surattense leaves total ethanol-extract (SSEE).Entities:
Keywords: Apoptosis; CCl4; DCFH; Hepatoprotection; Oxidative stress; Solanum surattense; β-sitosterol
Mesh:
Substances:
Year: 2019 PMID: 31269948 PMCID: PMC6610804 DOI: 10.1186/s12906-019-2553-1
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Fig. 1In vitro protection of cultured HepG2 cells by S. surattense ethanol-extract (SSEE). a MTT Cell proliferation assay showing attenuation of DCFH-induced oxidative damage. b apoptotic assay showing inhibition of DCFH-induced caspase-3/7 activation
Therapeutic effect of SSEE against CCl4-induced hepatotoxicity related parameters in rats
| Liver function parameters | GI (Control) | GII (CCl4-only) | GIII (CCl4+ SSEE 100 mg) | GIV (CCl4+ SSEE 200 mg) | GV (CCl4+ Silymarin 10 mg) |
|---|---|---|---|---|---|
| AST (U/L) | 107.45 ± 5.31 | 294.83 ± 8.33*** | 288.50 ± 7.36 b | 262.50 ± 6.87b | 136.66 ± 6.00**b |
| ALT (U/L) | 28.83 ± 2.20 | 230.83 ± 9.62***a | 198.16 ± 7.12*b | 159.50 ± 9.17***b | 85.66 ± 4.31***b |
| ALP (U/L) | 321.66 ± 13.8 | 515.16 ± 13.7***a | 479.00 ± 6.12* b | 436.33 ± 12.31**b | 396.33 ± 7.62***b |
| GGT (U/L) | 4.06 ± 0.32 | 12.85 ± 0.98***a | 11.38 ± 0.49b | 9.46 ± 0.32**b | 5.58 ± 0.28***b |
| BIL (mg/dL) | 0.54 ± 0.01 | 2.16 ± 0.08***a | 1.81 ± 0.05*b | 1.57 ± 0.06***b | 1.06 ± 0.06***b |
| TC (mg/dL) | 109.83 ± 3.9 | 206.00 ± 4.53***a | 179.50 ± 6.63**b | 168.83 ± 6.16*** | 147.66 ± 4.88***b |
| TG (mg/dL) | 59.01 ± 2.74 | 151.16 ± 4.61***a | 119.33 ± 3.8***b | 96.81 ± 3.75***b | 110.16 ± 5.26***b |
| HDL (mg/dL) | 55.18 ± 2.40 | 25.25 ± 1.79*** | 26.53 ± 1.22b | 36.28 ± 1.78**b | 40.41 ± 2.97**b |
| LDL (mg/dL) | 42.84 ± 3.22 | 149.51 ± 4.28***a | 130.10 ± 7.50*b | 113.18 ± 7.60**b | 85.21 ± 5.98***b |
| VLDL (mg/dL) | 11.80 ± 0.54 | 30.23 ± 0.92***a | 23.86 ± 0.76***b | 19.36 ± 0.75***b | 22.02 ± 1.05***b |
| TP (g/L) | 113.76 ± 2.8 | 49.11 ± 1.82***a | 53.88 ± 2.81b | 71.452.64***b | 91.81 ± 4.08***b |
| MDA (nmol/g) | 0.50 ± 0.02 | 4.82 ± 0.29***a | 4.47 ± 0.23b | 2.75 ± 0.1***b | 1.37 ± 0.16***b |
| NP-SH (nmol/g) | 7.39 ± 0.53 | 3.86 ± 0.44***a | 5.79 ± 0.35**b | 5.93 ± 0.31**b | 6.52 ± 0.31***b |
AST spartate aminotransaminase, ALT alanine aminotransaminase, ALP alkaline phosphatase, GGT γ-glutamyl transferase, BIL bilirubin, TC triglycerides, HDL high-density lipoproteins, LDL low-density lipoproteins, VLDL very low-density lipoproteins, TP total protein, MDA malondialdehyde, NP-SH nonprotein sulfhydryls. All values represent mean ± SEM. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ANOVA, followed by Dunnett’s multiple comparison test. aAs compared with control group (GI); bAs compared with CCl4-only group (GII)
Fig. 2Histopathology of experimental rat liver. Histograms showing (a) healthy tissues with normal central vein and hepatocytes; (b) CCl4-injured tissue with necrosis and fatty degenerative changes; (c) tissue with normal hepatocytes and central vein with full recovery after CCl4 plus SSEE (200 mg.kg.bw) treatment; and (d) tissue with normal hepatocytes and fully recovered central vein after CCl4 plus silymarin (10 mg.kg.bw) treatment. 1. Central vein; 2. Normal hepatocytes cord; 3. Focal necrosis; 4. Vacuoles of fatty degeneration; 5. Normal hepatic tissue; 5. Normal hepatic tissue
Fig. 3In vitro antioxidant activity of S. surattense ethanol-extract (SSEE). a DPPH radical scavenging activity of different concentrations (31.25–500 μg/mL) of total ethanol extract of S. surattense and standard antioxidant (Ascorbic acid). b β-carotene linoleic acid method showing β-carotene bleaching rate in presence of SSEE (500 μg/mL), gallic acid, blank control (left panel) and %inhibition of lipid peroxidation by different concentrations of SSEE (31.25–500 μg/mL) and gallic acid (right panel)
Fig. 4HPTLC standardization of β-sitosterol in the S. surattense ethanol-extract (SSEE, λ = 360 nm, mobile phase- hexane:ethyl acetate, 4:6, v/v). a chromatogram showing β-sitosterol biomarker (600 ng spot− 1, peak 1, Rf = 0.23); (b) chromatogram of SSEE containing β-sitosterol (peak 3, Rf = 0.23); (c) pictogram of developed and derivatized HPTLC plate of SSEE; (d) 3-D display of all tracks